Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)
(

Application Number		10595029	
Filing Date		2005-12-29	
First Named Inventor	Gabr	nela Chiosis	
Art Unit			
Examiner Name			
Attorney Docket Numb	er	MSK.P-072	

				U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	sue Date Name of Patentee of Applicant Rel				Lines where	
	1	6060598		2000-05-09	Devlin et al					
	2	4902630		1990-02-20	Bennett et al					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	iumber Kind Code <sup>1</sup> Publication Name of Patentee or Applicant of cited Document				Lines where			
			Code	Date	of cited Docu			ant Passag s Appear	es or Relev	all
	1	20020160496	Code	Date 2002-10-31	of cited Docu Gewirth et al				es or Relev	an
If you wis	Ċ	20020160496		2002-10-31	Gewirth et al	ment	Figure	s Appear	es or Relev	an
If you wis	Ċ		ished Ap	2002-10-31	Gewirth et al	please click the Ad	Figure	s Appear	es or Relev	all
Examiner	h to a		ished Ap	2002-10-31 plication citatio	Gewirth et al n information p	please click the Ad	Figure d buttor	Add Remove	umns,Lines evant or Relevant	
If you wis Examiner Initial*	h to a	dd additional U.S. Publ	ished Ap	2002-10-31 plication citatio	Gewirth et al	olease click the Ad ENTS  Name of Patente Applicant of cited	Figure d buttor	Add Remove Pages,Coll where Rele Passages	umns,Lines evant or Relevant	T
Examiner Initial*	Cite No	Foreign Document	Country Code <sup>2</sup>	2002-10-31 plication citatio FOREIGN PA Kind Code	Gewirth et al n information p TENT DOCUM Publication Date 2002-11-28	nent  Dease click the Ad  ENTS  Name of Patente Applicant of cited Document  Sloan-Keltering Int for Cancer Resear	d buttor	Remove Pages,Col	umns,Lines evant or Relevant	T

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number		10595029
	Filing Date		2005-12-29
	First Named Inventor	Gabriela Chiosis	
	Art Unit		
	Examiner Name		
	Attorney Docket Numb	er	MSK.P-072

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

# Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Knd Codes of USPTO Patent Documents at year LISPTO, GDU or MPEP 901.04. <sup>2</sup> Either office that issued the document, by the bo-later code (WIPO Standard ST3.) <sup>3</sup> Sor Juapanes patent concuments, by managed the common state of the Empower managed code the search counterful. <sup>4</sup> Knill of document by the appropriate symbols as adicated on the document under WIPO Standard ST.16 if possible. <sup>3</sup> Applicant is to place a check mark here if English Imaguage translation is attached.

#### 

### CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CPR 1.97(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a forting parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 159(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1978(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	Date (YYYY-MM-DD)	
Name/Drint	Registration Number	$\overline{}$

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR. 11.4 This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.